相关实验视频

Updated: Jun 21, 2025

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres

Published on: November 5, 2016

哈明和埃克森丁-4组合疗法在小鼠异种移植系统中 in vivo 安全扩大人类β细胞质量

Carolina Rosselot¹, Yansui Li¹, Peng Wang¹

¹Diabetes, Obesity and Metabolism Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

Science translational medicine

|July 10, 2024

概括

一项新的研究表明,将DYRK1A抑制剂与GLP1受体激动剂结合在一起,可显著增加人体β细胞体质 in vivo. 这种组合疗法通过增强β细胞增殖,功能和生存来逆转糖尿病.

科学领域:

内分泌学在内分泌学.
再生医学是一种再生医学.
药理学药理学是指药理学的学科.

背景情况:

糖尿病影响全球超过5.37亿人,其特点是胰岛素产生β细胞减少.
目前的糖尿病药物不会增加人类β细胞的数量.
双重氨酸调节激酶1A (DYRK1A) 抑制剂和葡萄糖类1受体激动剂 (GLP1RAs) 显示出β细胞再生的潜力.

研究的目的:

为了调查DYRK1A抑制剂与GLP1RAs相结合是否会在体内增加人类β细胞质量.
评估这种联合治疗对人类β细胞存活率和糖尿病逆转的影响.
评估这种治疗组合的临床前安全性.

主要方法:

使用了优化免疫标记启用的三维成像溶剂清除器官 (iDISCO+) 协议.
使用小鼠脏与人类小岛移植来模拟体内环境.
使用DYRK1A抑制剂与exendin-4 (一种GLP1RA) 结合使用.

主要成果:

在糖尿病和非糖尿病小鼠中,组合疗法在3个月内使人类β细胞质量增加了4至7倍.
在没有改变人类α细胞质量的治疗小鼠中,糖尿病逆转.
机制包括增强的β细胞增殖,功能和生存,其中VGF介导了生存益处的一部分.

结论:

DYRK1A抑制剂和GLP1RA的组合在体内显示出增加人类β细胞质量的显著治疗潜力.
这种方法为糖尿病治疗提供了一个有希望的策略,在逆转糖尿病方面显示出有效性和有利的临床前安全性.
这些发现支持对DYRK1A抑制剂和GLP1RAs用于治疗糖尿病的进一步临床研究.

更多相关视频

A High-content In Vitro Pancreatic Islet β-cell Replication Discovery Platform

A High-content In Vitro Pancreatic Islet β-cell Replication Discovery Platform

Published on: July 16, 2016

Intraportal Transplantation of Pancreatic Islets in Mouse Model

Intraportal Transplantation of Pancreatic Islets in Mouse Model

Published on: May 5, 2018

相关概念视频

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Insulin: Biosynthesis, Chemistry, and Preparation

Insulin: Biosynthesis, Chemistry, and Preparation

The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...